The FDA noted that "CAPA CA 90 was initiated on April 9, 2024, for 731 Series Ventilators with MRI compatibility nonconformances, resulting in a Class I recall that was not initiated until April 30, 2024." The company's complaint analysis system failed to detect the pattern because complaints were coded as "User Errors," "No Fault Found," "No Product Returned," and "User Attempted Repairs." These ventilator failures "caused malfunctions and shutdowns that led to the stoppage of ventilatory support and the need for alternative means of ventilation." Even after closing the CAPA as effective in September 2024, Zoll received 6 complaints relating to the MRI compatibility issues from November 15, 2024, through January 16, 2025, after closure of the CAPA and no additional CAPAs have been initiated
Prescription Weight Loss Programs Tailored to You Achieving and maintaining a healthy weight can be challenging without support
Retatrutides before-and-after data includes metabolic improvements that stand on their own clinical merit, separate from the headline weight loss numbers
Its publications are NDT, CKJ (Open Access journal), and the online educational portal NEP
Safety profile and side effects When considering the safety profile and side effects of semaglutide and Zepbound, it is important to recognize the similarities and differences that exist between these two medications: Common side effects: Nausea Diarrhea Vomiting Constipation Indigestion Stomach pain Abdominal pain Severe side effects: Hypoglycemia (low blood sugar) Pancreatitis (inflammation of the pancreas) Severe allergic reactions Gallbladder problems Both semaglutide and Zepbound carry a boxed warning regarding the risk of thyroid C-cell tumors, an important consideration for patients with a history of thyroid cancer
